Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2022

01-04-2022 | Fatty Liver | Original Article

Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

Authors: Sohrab Nobarani, Fariba Alaei-Shahmiri, Rokhsareh Aghili, Mojtaba Malek, Hossein Poustchi, Maryam Lahouti, Mohammad E. Khamseh

Published in: Digestive Diseases and Sciences | Issue 4/2022

Login to get access

Abstract

Aim

To explore the association of visceral adipose tissue (VAT) area and non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).

Methods

This was a cross-sectional study comprising 100 patients with T2DM and 100 non-T2DM individuals, matched for age, sex, and body mass index (BMI). Transient elastography was used to assess hepatic steatosis and liver stiffness measurements (LSM). Controlled attenuation parameter (CAP) was used to quantify hepatic steatosis. To distinguish grades of hepatic steatosis, cutoff values were as follows: S1 ≥ 302, S2 ≥ 331, and S3 ≥ 337 dB/m. Moreover, VAT area was measured by dual-energy X-ray absorptiometry in accordance with validated protocols.

Results

CAP score was significantly higher in participants with T2DM (294.61 ± 3.82 vs. 269.86 ± 3.86 dB/ m; P < 0.001). Furthermore, 42% of participants with T2DM had hepatic steatosis (S > S1: 302 dB/m), while this figure was 26% in non-T2DM group (P < 0.003). The mean liver stiffness measurement was also significantly higher in patients with T2DM (5.53 vs. 4.79 kPa; P < 0.001). VAT area was greater in patients with T2DM compared to non-T2DM individuals: 163.79 ± 47.98 cm2 versus 147.49 ± 39.09 cm2, P = 0.009. However, total and truncal fat mass were not different between the two groups. Age, BMI, waist circumference, ALT, CAP, and LSM were significantly associated with VAT area. BMI and VAT area were the important determinants of steatosis in both groups of participants with and without T2DM. Moreover, the VAT area was associated with the severity of hepatic steatosis and liver stiffness, independent of anthropometric measures of obesity.

Conclusion

VAT area is a major determinant of the severity of hepatic steatosis and liver stiffness in patient with T2DM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Verrijken A, Francque S, Van Gaal L. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. Eur J Endocrinol 2011;7:96–103.CrossRef Verrijken A, Francque S, Van Gaal L. The role of visceral adipose tissue in the pathogenesis of non-alcoholic fatty liver disease. Eur J Endocrinol 2011;7:96–103.CrossRef
2.
go back to reference Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Progr Lipid Res 2013;52:165–174.CrossRef Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Progr Lipid Res 2013;52:165–174.CrossRef
3.
go back to reference Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11–18.PubMedCrossRef Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11–18.PubMedCrossRef
4.
go back to reference Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27–42.PubMedCrossRef Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004;5:27–42.PubMedCrossRef
7.
go back to reference Bramlage KS, Bansal V, Xanthakos SA, Kohli R. Fatty liver disease in children—what should one do? Indian J Pediatr 2013;80:109–114.CrossRef Bramlage KS, Bansal V, Xanthakos SA, Kohli R. Fatty liver disease in children—what should one do? Indian J Pediatr 2013;80:109–114.CrossRef
8.
go back to reference Vernon G, Baranova A, Younossi Z. Therapeutics. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol 2011;34:274–285.CrossRef Vernon G, Baranova A, Younossi Z. Therapeutics. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol 2011;34:274–285.CrossRef
9.
go back to reference Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010;256:640–647.PubMedCrossRef Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010;256:640–647.PubMedCrossRef
10.
go back to reference Kim BH, Lee JM, Lee YJ, Lee KB, Suh KS, Han JK et al. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Resonance Imaging 2011;34:1110–1116.CrossRef Kim BH, Lee JM, Lee YJ, Lee KB, Suh KS, Han JK et al. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Resonance Imaging 2011;34:1110–1116.CrossRef
11.
go back to reference Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259:749–756.PubMedPubMedCentralCrossRef Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011;259:749–756.PubMedPubMedCentralCrossRef
12.
go back to reference Kim H-J, Lee H-K, Cho J-H, Yang H-J. Quantitative comparison of transient elastography (TE), shear wave elastography (SWE) and liver biopsy results of patients with chronic liver disease. J Phys Therapy Sci 2015;27:2465–2468.CrossRef Kim H-J, Lee H-K, Cho J-H, Yang H-J. Quantitative comparison of transient elastography (TE), shear wave elastography (SWE) and liver biopsy results of patients with chronic liver disease. J Phys Therapy Sci 2015;27:2465–2468.CrossRef
13.
go back to reference Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717–1730.PubMedCrossRef Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156:1717–1730.PubMedCrossRef
14.
go back to reference Dixon JB, Bhathal PS, O’brien PE, . Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.PubMedCrossRef Dixon JB, Bhathal PS, O’brien PE, . Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.PubMedCrossRef
15.
16.
go back to reference Lee HW, Kim KJ, Jung KS, Chon YE, Huh JH, Park KH et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PloS ONE 2017;12:e0187066.PubMedPubMedCentralCrossRef Lee HW, Kim KJ, Jung KS, Chon YE, Huh JH, Park KH et al. The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PloS ONE 2017;12:e0187066.PubMedPubMedCentralCrossRef
17.
go back to reference Salgado ALFDA, Carvalho LD, Oliveira AC, Santos VND, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol 2010;47:165–169.PubMedCrossRef Salgado ALFDA, Carvalho LD, Oliveira AC, Santos VND, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol 2010;47:165–169.PubMedCrossRef
18.
go back to reference Zulet MA, Bondia-Pons I, Abete I, Iglesia R, Lopez-Legarrea P, Forga L et al. The reduction of the metabolyc syndrome in Navarra-Spain (RESMENA-S) study; a multidisciplinary strategy based on chrononutrition and nutritional education, together with dietetic and psychological control. Nutr Hosp 2011;26:16–26.PubMed Zulet MA, Bondia-Pons I, Abete I, Iglesia R, Lopez-Legarrea P, Forga L et al. The reduction of the metabolyc syndrome in Navarra-Spain (RESMENA-S) study; a multidisciplinary strategy based on chrononutrition and nutritional education, together with dietetic and psychological control. Nutr Hosp 2011;26:16–26.PubMed
19.
go back to reference Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obes Rev 2012;20:1313–1318.CrossRef Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obes Rev 2012;20:1313–1318.CrossRef
20.
go back to reference Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol Hepatol 2010;24:661–670. Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol Hepatol 2010;24:661–670.
21.
go back to reference Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–350.PubMedCrossRef Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–350.PubMedCrossRef
22.
go back to reference Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793–801.PubMedCrossRef Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793–801.PubMedCrossRef
23.
go back to reference Oz I, Bilici M, Serifoglu I, Arpaci DK, Buyukuysal M, Bayraktaroglu T. Association of pancreas volume and insulin resistance with abdominal fat distribution in type-2 diabetes as evaluated by computed tomography. Acta Endocrinol 2017;13:168. Oz I, Bilici M, Serifoglu I, Arpaci DK, Buyukuysal M, Bayraktaroglu T. Association of pancreas volume and insulin resistance with abdominal fat distribution in type-2 diabetes as evaluated by computed tomography. Acta Endocrinol 2017;13:168.
24.
go back to reference Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY. Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. Diabetes Care 2013;36:289–293.PubMedPubMedCentralCrossRef Wander PL, Boyko EJ, Leonetti DL, McNeely MJ, Kahn SE, Fujimoto WY. Change in visceral adiposity independently predicts a greater risk of developing type 2 diabetes over 10 years in Japanese Americans. Diabetes Care 2013;36:289–293.PubMedPubMedCentralCrossRef
25.
go back to reference Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012;308:1150–1159.PubMedPubMedCentralCrossRef Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012;308:1150–1159.PubMedPubMedCentralCrossRef
26.
go back to reference Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging 2014;7:1221–1235.PubMedPubMedCentralCrossRef Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine AB et al. Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study. JACC Cardiovasc Imaging 2014;7:1221–1235.PubMedPubMedCentralCrossRef
27.
go back to reference Fox C, Massaro J, Hoffmann U, Pou K, Maurovich-Horvat P, Liu C. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48. J Allergy Clin Immunol. 2004;121. Fox C, Massaro J, Hoffmann U, Pou K, Maurovich-Horvat P, Liu C. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48. J Allergy Clin Immunol. 2004;121.
28.
go back to reference McLaughlin T, Lamendola C, Liu A, Abbasi F. Metabolism. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol 2011;96:E1756–E1760.CrossRef McLaughlin T, Lamendola C, Liu A, Abbasi F. Metabolism. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol 2011;96:E1756–E1760.CrossRef
29.
go back to reference Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity 2010;18:2191–2198.PubMedCrossRef Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity 2010;18:2191–2198.PubMedCrossRef
30.
go back to reference Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity 2006;14:S16–S19.CrossRef Bergman RN, Kim SP, Catalano KJ, Hsu IR, Chiu JD, Kabir M et al. Why visceral fat is bad: mechanisms of the metabolic syndrome. Obesity 2006;14:S16–S19.CrossRef
31.
go back to reference Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem 2011;44:281–287.PubMedCrossRef Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem 2011;44:281–287.PubMedCrossRef
32.
go back to reference Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32.PubMedCrossRef Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32.PubMedCrossRef
33.
go back to reference Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139:448–455.PubMedCrossRef Fabbrini E, Tamboli RA, Magkos F, Marks-Shulman PA, Eckhauser AW, Richards WO et al. Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology 2010;139:448–455.PubMedCrossRef
34.
go back to reference Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549–2557.PubMedCrossRef Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2549–2557.PubMedCrossRef
35.
go back to reference Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci 2009;106:15430–15435.PubMedPubMedCentralCrossRef Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci 2009;106:15430–15435.PubMedPubMedCentralCrossRef
36.
go back to reference Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity 2010;18:1510–1515.PubMedCrossRef Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity 2010;18:1510–1515.PubMedCrossRef
37.
go back to reference Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digest Liver Dis 2015;47:181–190.CrossRef Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Digest Liver Dis 2015;47:181–190.CrossRef
38.
go back to reference Gletsu-Miller N, Kahn HS, Gasevic D, Liang Z, Frediani JK, Torres WE et al. Sagittal abdominal diameter and visceral adiposity. Obes Surg 2013;23:874–881.PubMedPubMedCentralCrossRef Gletsu-Miller N, Kahn HS, Gasevic D, Liang Z, Frediani JK, Torres WE et al. Sagittal abdominal diameter and visceral adiposity. Obes Surg 2013;23:874–881.PubMedPubMedCentralCrossRef
40.
go back to reference Garg A. Metabolism. Regional adiposity and insulin resistance. J Clin Endocrinol 2004;89:4206–4210.CrossRef Garg A. Metabolism. Regional adiposity and insulin resistance. J Clin Endocrinol 2004;89:4206–4210.CrossRef
41.
go back to reference Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 2013;21:E439–E447.PubMedCrossRef Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 2013;21:E439–E447.PubMedCrossRef
42.
go back to reference Hussain A, Claussen B, Ramachandran A, Williams R. Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2007;76:317–326.PubMedCrossRef Hussain A, Claussen B, Ramachandran A, Williams R. Prevention of type 2 diabetes: a review. Diabetes Res Clin Pract 2007;76:317–326.PubMedCrossRef
43.
go back to reference Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579–1585.PubMedCrossRef Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579–1585.PubMedCrossRef
44.
go back to reference Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovasc Diabetol 2009;8:44.PubMedPubMedCentralCrossRef Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type. Cardiovasc Diabetol 2009;8:44.PubMedPubMedCentralCrossRef
45.
go back to reference van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449–457.PubMedCrossRef van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008;48:449–457.PubMedCrossRef
46.
go back to reference Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640–1645.PubMedCrossRef Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009;120:1640–1645.PubMedCrossRef
47.
go back to reference Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health: association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Obesity 2007;15:1061–1067.PubMedCrossRef Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health: association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Obesity 2007;15:1061–1067.PubMedCrossRef
48.
go back to reference Bi X, Seabolt L, Shibao C, Buchowski M, Kang H, Keil C et al. DXA-measured visceral adipose tissue predicts impaired glucose tolerance and metabolic syndrome in obese Caucasian and African-American women. Eur J Clin Nutr 2015;69:329–336.PubMedCrossRef Bi X, Seabolt L, Shibao C, Buchowski M, Kang H, Keil C et al. DXA-measured visceral adipose tissue predicts impaired glucose tolerance and metabolic syndrome in obese Caucasian and African-American women. Eur J Clin Nutr 2015;69:329–336.PubMedCrossRef
49.
go back to reference Millar SR, Perry IJ, Phillips CM. Assessing cardiometabolic risk in middle-aged adults using body mass index and waist–height ratio: are two indices better than one? A cross-sectional study. Diabetol Metab Syndr 2015;7:73.PubMedPubMedCentralCrossRef Millar SR, Perry IJ, Phillips CM. Assessing cardiometabolic risk in middle-aged adults using body mass index and waist–height ratio: are two indices better than one? A cross-sectional study. Diabetol Metab Syndr 2015;7:73.PubMedPubMedCentralCrossRef
50.
go back to reference Zhang W, Huang R, Wang Y, Rao H, Wei L, Su GL et al. Fat accumulation, liver fibrosis, and metabolic abnormalities in Chinese patients with moderate/severe versus mild hepatic steatosis. Hepatol Commun 2019;3:1585–1597.PubMedPubMedCentralCrossRef Zhang W, Huang R, Wang Y, Rao H, Wei L, Su GL et al. Fat accumulation, liver fibrosis, and metabolic abnormalities in Chinese patients with moderate/severe versus mild hepatic steatosis. Hepatol Commun 2019;3:1585–1597.PubMedPubMedCentralCrossRef
51.
go back to reference Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol 2011;46:70–78.PubMedCrossRef Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol 2011;46:70–78.PubMedCrossRef
52.
go back to reference Yu SJ, Kim W, Kim D, Yoon J-H, Lee K, Kim JH et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine 2015;94:e2159.PubMedPubMedCentralCrossRef Yu SJ, Kim W, Kim D, Yoon J-H, Lee K, Kim JH et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine 2015;94:e2159.PubMedPubMedCentralCrossRef
53.
go back to reference Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 2018;137:1391–1406.PubMedPubMedCentralCrossRef Neeland IJ, Poirier P, Després J-P. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation 2018;137:1391–1406.PubMedPubMedCentralCrossRef
54.
go back to reference Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17:510–519.PubMedCrossRef Li L, Liu DW, Yan HY, Wang ZY, Zhao SH, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev 2016;17:510–519.PubMedCrossRef
55.
go back to reference Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873.PubMedCrossRef Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873.PubMedCrossRef
56.
go back to reference Kwok R, Choi KC, Wong GL-H, Zhang Y, Chan HL-Y, Luk AO-Y et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016;65:1359–1368.PubMedCrossRef Kwok R, Choi KC, Wong GL-H, Zhang Y, Chan HL-Y, Luk AO-Y et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 2016;65:1359–1368.PubMedCrossRef
57.
go back to reference Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63:138–147.PubMedCrossRef Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology. 2016;63:138–147.PubMedCrossRef
Metadata
Title
Visceral Adipose Tissue and Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
Authors
Sohrab Nobarani
Fariba Alaei-Shahmiri
Rokhsareh Aghili
Mojtaba Malek
Hossein Poustchi
Maryam Lahouti
Mohammad E. Khamseh
Publication date
01-04-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06953-z

Other articles of this Issue 4/2022

Digestive Diseases and Sciences 4/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.